True North Labs

Author: labstruenorth@gmail.com

  • Arch Biopartners to Expand LSALT Peptide Trial into the United States

    Arch Biopartners to Expand LSALT Peptide Trial into the United States

    Arch Biopartners has announced plans to expand its ongoing clinical trial of the LSALT peptide into the United States, marking a significant step forward for the company’s research program. LSALT peptide is being studied as a potential therapeutic option, and this expansion reflects growing confidence in the compound’s development pathway as well as an effort to broaden the pool of patients who can participate in the research.

    Expanding a clinical trial into new geographic markets like the US often signals that a therapy has cleared important early hurdles and that sponsors see enough promise to invest in larger-scale, more diverse patient enrollment. Access to the US clinical trial infrastructure can also mean faster recruitment, access to specialized medical centers, and the possibility of engaging with regulators such as the FDA earlier in the development process.

    For patients and researchers following peptide-based therapeutics, this kind of expansion is an encouraging sign. It suggests that Arch Biopartners is building a more robust body of clinical evidence, which is a critical part of moving any investigational treatment closer to potential approval. Broader trial participation can also help ensure that findings are more representative and applicable across different patient populations.

    While it’s still early in the process, developments like this highlight the ongoing momentum in the peptide therapeutics space, where companies continue to invest in expanding research infrastructure to better understand how these molecules might benefit patients. As the trial progresses in the US, the peptide research community will be watching for updates on enrollment, study design, and eventual results.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Arch Biopartners plans US expansion of LSALT peptide trial – Yahoo

  • New Clinical Trial Explores How Leucine Dosing Could Help Preserve Muscle During Fasting-Based Weight Loss

    New Clinical Trial Explores How Leucine Dosing Could Help Preserve Muscle During Fasting-Based Weight Loss

    A new clinical trial registered on ClinicalTrials.gov is set to investigate an important question for anyone interested in weight management: can the amino acid leucine help preserve muscle mass during structured fasting periods? The study will enroll 100 young men between the ages of 21 and 35 to complete a four-week alternate-day fasting (ADF) program, with researchers testing four different leucine doses to see whether a dose-response relationship exists for muscle maintenance.

    Alternate-day fasting has grown in popularity as a weight management strategy, but one common concern is that fasting periods can sometimes lead to loss of lean muscle mass alongside fat loss. This trial aims to address that concern directly by pairing a carefully controlled fasting protocol with varying leucine intake—ranging from 0.02 to 0.08 grams per kilogram of body weight per meal. Leucine is a branched-chain amino acid long recognized for its role in stimulating muscle protein synthesis, making it a logical candidate for this kind of investigation.

    What makes this study particularly promising is its rigor: all meals will be provided to participants, ensuring consistent protein and caloric intake across fasting and feeding days, and the leucine dosing will be double-blind to reduce bias in the results. Researchers will track a wide range of outcomes, including body composition, blood parameters, waist-to-hip ratio, mood, stress levels, and appetite-related measures before and after the four-week program. This comprehensive approach could yield valuable insights not just into muscle preservation, but into the broader physical and psychological effects of combining targeted amino acid supplementation with intermittent fasting.

    If the hypothesized dose-response relationship holds true, the findings could help shape more effective, muscle-sparing approaches to fasting-based weight loss programs. This could be especially meaningful for individuals seeking to manage body composition without sacrificing lean tissue—a common challenge in many weight loss strategies. Because the study focuses on generally healthy young men without underlying cardiovascular, metabolic, or kidney conditions, it also reflects a thoughtfully controlled research design aimed at generating clear, interpretable data.

    As this trial gets underway, it represents an encouraging step toward better understanding how simple nutritional strategies, like optimizing leucine intake, might support healthier outcomes during periods of caloric restriction. Results from studies like this one could eventually inform more personalized and effective approaches to weight management that prioritize preserving muscle alongside fat loss. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Dose Response of Leucine on Muscle Maintenance During Weight Loss

  • New Clinical Trial Aims to Improve Diabetes and Celiac Disease Screening for Underserved Communities

    A new clinical trial, known as ACCESS-T1D, has been launched to address a critical gap in healthcare: early detection of Type 1 diabetes (T1D) and celiac disease (CD) in underserved populations. Listed on ClinicalTrials.gov, the study focuses on improving screening methods so that these conditions can be identified sooner, particularly in communities that have historically faced barriers to consistent medical care.

    Type 1 diabetes involves the body’s immune system attacking insulin-producing cells, and insulin itself is a naturally occurring peptide hormone essential for regulating blood sugar. Because T1D and celiac disease often go undiagnosed until symptoms become severe, early screening initiatives like this one could make a meaningful difference in outcomes. Catching these conditions earlier may allow individuals to begin appropriate care sooner, potentially reducing complications and improving long-term quality of life.

    What makes this trial especially encouraging is its explicit focus on underserved children and adults—groups that are frequently underrepresented in medical research and often face greater obstacles in accessing routine screenings. By designing a study specifically to reach these populations, researchers are working to close a longstanding equity gap in diabetes and celiac disease detection. Improved access to screening can also mean more people receive timely referrals to specialists and diabetes management resources, including insulin therapy when needed.

    Efforts like ACCESS-T1D reflect a broader, positive trend in clinical research: prioritizing accessibility alongside scientific advancement. Rather than solely testing new treatments, this study emphasizes strengthening the front end of the healthcare journey—identification and diagnosis—which is foundational to ensuring that beneficial therapies, including insulin and other peptide-based treatments, reach the people who need them as early as possible.

    As this trial progresses, it may offer valuable insights into how screening programs can be better tailored to reach underserved communities, potentially serving as a model for future public health initiatives. This information is provided for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)

  • New Clinical Trial Explores BOTOX for Masseter Muscle Prominence

    A new clinical trial is underway to evaluate the safety and effectiveness of onabotulinumtoxinA, better known as BOTOX, for treating Masseter Muscle Prominence (MMP) — a condition where the jaw muscles used for chewing appear more pronounced than some individuals would like. This development highlights the ongoing exploration of botulinum toxin’s versatility beyond its well-known cosmetic and therapeutic uses for wrinkles and muscle spasms.

    The study, registered on ClinicalTrials.gov, will enroll approximately 200 adult participants across roughly 20 sites in the United States. Researchers are using a carefully designed two-period approach: in the first phase, participants will be randomly assigned to receive either BOTOX or a placebo injection into the masseter muscles on both sides of the face. This rigorous, placebo-controlled design helps ensure that any observed benefits can be confidently attributed to the treatment itself rather than other factors.

    Notably, the trial also includes an optional second phase where eligible participants can receive an open-label BOTOX retreatment, allowing researchers to gather valuable data on repeated dosing and longer-term outcomes. Participants will be closely monitored through regular visits, medical assessments, and questionnaires over a follow-up period of up to six months, reflecting a thorough commitment to participant safety and data quality.

    If successful, this research could pave the way for an additional, minimally invasive option for individuals seeking to address masseter prominence without surgery. Botulinum toxin injections are already widely used and understood for their muscle-relaxing properties, and expanding their studied applications to include this specific cosmetic and functional concern reflects the growing versatility of peptide-based and neurotoxin therapies in modern aesthetic medicine.

    Clinical trials like this one are an essential part of bringing safe, well-studied treatments to patients. By rigorously testing both efficacy and safety in a controlled setting, researchers aim to provide clearer answers for individuals who may benefit from this type of treatment in the future. As with all clinical research, results will need to be published and peer-reviewed before any conclusions can be drawn about the treatment’s broader availability or effectiveness.

    This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare provider for guidance on any treatment options.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants

  • Pfizer’s Berobenatide Shows Promise in Phase IIb Trial

    Pfizer’s Berobenatide Shows Promise in Phase IIb Trial

    Pfizer has reported positive outcomes from a Phase IIb clinical trial evaluating berobenatide, an investigational peptide therapeutic. The announcement adds to a growing body of evidence supporting the potential of peptide-based approaches in modern medicine, and represents a meaningful milestone as the compound progresses through the clinical development pipeline.

    Phase IIb trials are a critical checkpoint in drug development, designed to further establish efficacy and safety in a larger patient population after initial proof-of-concept studies. Achieving positive results at this stage suggests that berobenatide is demonstrating the kind of consistent performance that can support advancement into larger, late-stage Phase III trials — often the final step before regulatory review.

    Peptide therapeutics like berobenatide continue to attract significant interest from major pharmaceutical companies because of their ability to combine the precision of biologic drugs with the manufacturing advantages of smaller molecules. This class of treatment has already produced several notable success stories in recent years, and continued positive trial data from a company with Pfizer’s scale and resources underscores the ongoing momentum behind peptide-based drug development.

    While specific details about the mechanism, target condition, and full data set from this trial were not extensively detailed in the initial announcement, the fact that the study met its goals is an encouraging signal for patients and the broader research community. Successful mid-stage trials help pave the way for expanded studies, additional regulatory engagement, and eventually, if all goes well, new treatment options reaching the people who need them.

    True North Labs will continue to monitor developments related to berobenatide as more information becomes available, including any future trial designs, patient populations, and regulatory milestones. As always, we’re glad to see continued investment and positive momentum in peptide science.

    This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance on any treatment or therapy.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Pfizer reports positive results from Phase IIb trial of berobenatide – Clinical Trials Arena

  • GV1001 Peptide Shows Promise Against Alzheimer’s Disease in Mouse Study

    GV1001 Peptide Shows Promise Against Alzheimer’s Disease in Mouse Study

    Researchers publishing in Experimental & Molecular Medicine have reported that GV1001, a peptide derived from human telomerase reverse transcriptase, was able to rescue signs of neurodegeneration in a mouse model of Alzheimer’s disease. The study adds to a growing body of research exploring how peptide-based approaches might help address the complex biological changes seen in neurodegenerative conditions.

    GV1001 has previously been studied for its potential roles in cellular protection and immune modulation, but this new work focused specifically on its effects within the brain. In the mouse model used to mimic aspects of Alzheimer’s disease, treatment with the peptide was associated with improvements in markers of neurodegeneration, suggesting that it may help support neuronal health under disease-related stress.

    While the exact mechanisms are still being investigated, the researchers point to GV1001’s known biological activities—including potential effects on cellular stress responses—as possible explanations for the observed benefits. Alzheimer’s disease remains one of the most challenging conditions to treat, largely because it involves multiple overlapping processes, including protein aggregation, inflammation, and progressive neuronal loss. Any research pathway that shows measurable improvement in animal models is considered a meaningful step forward by the scientific community.

    It’s important to note that this research was conducted in a mouse model, and translating findings from animal studies to human treatments is a long and rigorous process involving further preclinical work and, eventually, human clinical trials. Still, this study contributes valuable insight into how telomerase-derived peptides might be leveraged in future neuroscience research, and it opens the door to further investigation into GV1001’s potential role in supporting brain health.

    As with all emerging peptide research, these findings are early-stage and highlight promising directions rather than ready-to-use treatments. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease | Experimental & Molecular Medicine – nature.com

  • Arch Biopartners Set to Expand LSALT Peptide Clinical Trial into the United States

    Arch Biopartners Set to Expand LSALT Peptide Clinical Trial into the United States

    Arch Biopartners has announced plans to expand its ongoing clinical trial for LSALT peptide into the United States, marking a significant step forward for the company’s drug development program. LSALT peptide is an investigational therapy that has been under study for its potential to help protect organs during periods of acute stress, such as major surgery or critical illness.

    Expanding a clinical trial into a new country, particularly one with a large and diverse patient population like the US, is often viewed as a positive sign of progress. It typically indicates that earlier trial phases have generated encouraging enough data to justify broader investment and regulatory engagement. A larger, more geographically diverse trial can also help researchers gather more robust evidence about how a treatment performs across different patient populations, which is valuable for eventual regulatory review.

    For patients and clinicians, the expansion of trial sites means more opportunities for eligible individuals to participate in cutting-edge research and potentially access an investigational therapy before it becomes widely available. It also reflects the broader momentum in the peptide therapeutics space, where companies are increasingly exploring how short protein fragments can be harnessed to address complex medical challenges, including organ protection and inflammation management.

    Arch Biopartners’ move to grow its US footprint suggests confidence in the LSALT peptide program and a commitment to advancing the science through rigorous clinical evaluation. As with all early and mid-stage drug development programs, continued trial expansion and data collection will be important steps on the path toward understanding the full potential of this therapy.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Arch Biopartners plans US expansion of LSALT peptide trial – Clinical Trials Arena

  • GV1001 Peptide Shows Promise Against Neurodegeneration in Alzheimer’s Mouse Study

    Researchers have published encouraging findings in Experimental & Molecular Medicine describing how GV1001, a peptide derived from human telomerase reverse transcriptase, was able to rescue signs of neurodegeneration in a mouse model of Alzheimer’s disease. The study adds to a growing body of research exploring how peptide-based approaches might one day help address the underlying biology of neurodegenerative conditions rather than just their symptoms.

    GV1001 has an interesting history: it was originally studied as a cancer vaccine candidate because of its connection to telomerase activity, but scientists have increasingly discovered that this same peptide appears to have protective effects on cells under stress, including neurons. In this latest mouse study, the peptide appeared to counteract markers of neurodegeneration, suggesting it may help preserve brain cell health or function in the presence of Alzheimer’s-related pathology.

    What makes this finding particularly exciting is the possibility that a single peptide with a well-characterized safety profile from prior cancer research could be repurposed for an entirely different and pressing medical need. Alzheimer’s disease remains one of the most challenging conditions in medicine, with limited treatment options that meaningfully alter its course. Any research pointing toward new mechanisms of neuroprotection is a welcome development for the field.

    While this work was conducted in mice and will need to be followed by further research, including studies to confirm how GV1001 exerts its protective effects and whether similar benefits could translate to humans, it represents a meaningful step forward. Peptide-based therapeutics continue to expand into new therapeutic areas, and findings like this help illustrate the versatility of these molecules beyond their original intended use.

    As with all early-stage research, continued studies will be needed to fully understand GV1001’s potential role in neurodegenerative disease. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease | Experimental & Molecular Medicine – Nature

  • FDA Advisory Panel Backs Expanded Access to Compounded Peptides

    FDA Advisory Panel Backs Expanded Access to Compounded Peptides

    In a notable step for the peptide therapeutics space, an FDA advisory panel has voted in favor of adding certain peptides to the list of substances permitted for pharmacy compounding. This decision, if it moves forward through the FDA’s broader regulatory process, could open the door for licensed compounding pharmacies to prepare these peptide formulations for patients under physician guidance.

    Compounding pharmacies play an important role in the U.S. healthcare system, often providing personalized formulations when commercially manufactured products don’t meet a specific patient’s needs—whether due to dosage requirements, allergies to inactive ingredients, or supply shortages. Adding peptides to this permitted list represents a meaningful expansion of the tools available to prescribers and compounders working to meet patient needs.

    The panel’s vote reflects growing recognition within regulatory circles of the therapeutic potential peptides offer across multiple areas of medicine, from metabolic health to recovery and beyond. While the FDA’s own scientific staff reportedly expressed some reservations during the discussion—a normal part of the rigorous, multi-perspective review process the agency uses—the panel ultimately determined that the potential benefits to patient access warranted moving forward. This kind of thorough deliberation, weighing diverse expert viewpoints, is exactly the kind of careful process that helps build a responsible regulatory framework for emerging therapies.

    For the peptide community, this development signals continued momentum toward greater legitimacy and accessibility. As the compounding landscape evolves, patients working with knowledgeable healthcare providers may find more options available to them, supported by pharmacies operating under FDA-recognized standards rather than in regulatory gray areas.

    It’s worth noting that this vote is a recommendation, and the FDA will need to take further steps before any changes to the compounding list become official. As always, we’ll continue to follow this story as it develops. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists – The Hill

  • FDA Panel Gives Nod to 6 Peptides, Signaling Path Forward for Access

    In a development that peptide enthusiasts and researchers have been watching closely, an FDA advisory panel recently reviewed and backed six peptide compounds, offering a potential glimpse into how these increasingly popular substances may be regulated going forward. While advisory panel recommendations are not final rulings, they often carry significant weight in shaping the agency’s eventual decisions and can signal a more defined regulatory pathway for compounds that have existed in something of a gray area.

    Peptides have surged in popularity over recent years, both in clinical research settings and among consumers interested in wellness and recovery applications. However, much of that growth has occurred without the kind of clear regulatory framework that helps ensure consistency, quality, and safety across the market. A formal review process—especially one resulting in support from an expert panel—suggests movement toward more structured oversight, which many in the field see as a net positive for both innovation and consumer confidence.

    For companies developing peptide-based products and for researchers studying their potential applications, panel endorsements like this one can serve as an encouraging signal. Clearer regulatory guidance often translates into more predictable pathways for further study, funding, and eventual product development. It can also help legitimate manufacturers distinguish themselves in a marketplace that has sometimes been muddied by inconsistent quality control.

    While specifics of which six peptides received backing and the exact scope of the panel’s recommendations matter a great deal for those following this space closely, the broader takeaway is one of forward motion. Advisory panels typically weigh available safety and efficacy data before offering their support, meaning this step reflects a level of scientific scrutiny that can ultimately benefit the field by weeding out weaker candidates while allowing more promising compounds to advance.

    As with any regulatory process, next steps will likely include further agency review, potential public comment periods, and eventual rulemaking or guidance documents. True North Labs will continue to monitor how this panel’s recommendations translate into concrete policy, as clearer rules of the road for peptides could open new doors for research, product development, and responsible consumer access alike.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: An FDA Panel Just Backed 6 Peptides—Here’s What to Know – EatingWell